Results from a randomized, phase 2 clinical trial show that adding high-dose, intravenous (IV) vitamin C to chemotherapy doubles the overall survival of patients with late-stage metastatic pancreatic cancer from eight months to 16 months. "The results were so strong in showing the benefit of this therapy for patient survival that we were able to stop the trial early." In the study, 34 patients with stage 4 metastatic pancreatic cancer were randomized to receive either standard chemotherapy (gemcitabine and nab-paclitaxel), or chemotherapy plus infusions of high-dose vitamin C. The results showed that average overall survival was 16 months for the...